Organon & Co | OGN - Себестоимость





Себестоимость Изменить Дата
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Celltrion KRW 107.42B 295.44B 2025-12
Cspc Pharmaceutical CNY 2.11B 173.58M 2025-12
Deva Holding AS TRY 991.13M 182.81M 2023-09
Divis Laboratories Ltd INR 10.63B 1.23B 2025-12
Gilead Sciences USD 1.44B 174M 2026-03
Glaxosmithkline GBP 3.47B 461.37M 2025-12
Kangmei Pharma CNY 1.11B 84.66M 2025-09
Knight Therapeutics CAD 82.22M 1.03M 2025-12
Laboratorios Farma EUR 186.09M 11.06M 2023-12
Medical Developments International AUD 7.09M 4.91M 2025-12
Merck USD 2.94B 380M 2026-03
Neuren Pharmaceuticals AUD 7.45M 6.56M 2025-06
Novartis USD 3.54B 7M 2025-12
Organigram Holdings CAD 56.93M 20.53M 2025-12
Organon & Co USD 766M 21M 2025-12
Pharma Mar EUR 3.66M 116K 2026-03
Qiagen NV USD 217.43M 29.65M 2025-12
Sartorius EUR 484.6M 46.6M 2026-03
Sino Biopharmaceutical CNY 3.08B 589.65M 2025-06
Tilray USD 164.37M 8.41M 2025-09
Zealand Pharma A/S 410K 5K 2025-06